PL376659A1 - Skondensowane związki heterocykliczne - Google Patents

Skondensowane związki heterocykliczne

Info

Publication number
PL376659A1
PL376659A1 PL376659A PL37665903A PL376659A1 PL 376659 A1 PL376659 A1 PL 376659A1 PL 376659 A PL376659 A PL 376659A PL 37665903 A PL37665903 A PL 37665903A PL 376659 A1 PL376659 A1 PL 376659A1
Authority
PL
Poland
Prior art keywords
heterocyclic compounds
fused heterocyclic
fused
compounds
heterocyclic
Prior art date
Application number
PL376659A
Other languages
English (en)
Inventor
Xi Chen
Xiaoqi Chen
Pingchen Fan
Juan Jaen
Leping Li
Jeffrey T. Mihalic
Original Assignee
Tularik Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc. filed Critical Tularik Inc.
Publication of PL376659A1 publication Critical patent/PL376659A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL376659A 2002-11-06 2003-11-06 Skondensowane związki heterocykliczne PL376659A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42445602P 2002-11-06 2002-11-06

Publications (1)

Publication Number Publication Date
PL376659A1 true PL376659A1 (pl) 2006-01-09

Family

ID=32312811

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376659A PL376659A1 (pl) 2002-11-06 2003-11-06 Skondensowane związki heterocykliczne

Country Status (16)

Country Link
US (2) US7253179B2 (pl)
EP (1) EP1562943A1 (pl)
JP (1) JP4547266B2 (pl)
KR (1) KR20050103184A (pl)
CN (2) CN101134757A (pl)
AU (1) AU2003285160B2 (pl)
BR (1) BR0316070A (pl)
CA (1) CA2505372A1 (pl)
EA (1) EA009421B1 (pl)
IS (1) IS7833A (pl)
MX (1) MXPA05004739A (pl)
NO (1) NO20052655L (pl)
NZ (1) NZ540328A (pl)
PL (1) PL376659A1 (pl)
WO (1) WO2004043958A1 (pl)
ZA (1) ZA200503654B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
MXPA05004739A (es) * 2002-11-06 2005-08-02 Tularik Inc Compuestos heterociclicos fusionados.
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
DE102010025663A1 (de) * 2010-06-30 2012-01-05 Karl-Heinz Glüsenkamp Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
JP2013538800A (ja) 2010-08-10 2013-10-17 アッヴィ・インコーポレイテッド 新規trpv3モジュレーター
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
CN104254522A (zh) 2011-10-24 2014-12-31 艾伯维公司 作为trpv3调节剂的甲醇衍生物
CN106588812B (zh) * 2016-12-07 2019-02-22 烟台大学 一种酰氯制备2,4-二取代噻唑啉类化合物的方法
AU2020210117B2 (en) * 2019-01-14 2025-03-13 Zydus Lifesciences Limited Novel substituted sulfonylurea derivatives
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US23085A (en) * 1859-03-01 chandler
US176694A (en) * 1876-04-25 Improvement in screw-cutting die-stocks
US199549A (en) * 1878-01-22 Improvement in screw-propellers
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
EP0257701A1 (en) 1986-08-15 1988-03-02 Cedona Pharmaceuticals B.V. A process for preparing hydroxyl derivatives of compounds containing a carbazole, dibenzofurane or dibenzothiophene group
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
ES2173866T3 (es) 1991-07-05 2002-11-01 Glaxosmithkline Spa Derivados de hidroisoquinolina.
FI942499A7 (fi) 1992-09-29 1994-07-27 Toray Industries Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
US5272146A (en) 1992-10-02 1993-12-21 The United States Of America As Represented By The United States Department Of Health And Human Services 1,2-dihydroellipticines with activity against CNS specific cancer cell lines
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
ES2217533T3 (es) 1997-01-16 2004-11-01 Toray Industries, Inc. Derivados de indolomorfinano y medicamentos/preventivos para transtornos cerebrales.
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1999028492A1 (en) 1997-12-03 1999-06-10 Smithkline Beecham Corporation A method of finding agonist and antagonist to human 11cb splice variant
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU6035999A (en) 1998-09-17 2000-04-03 Incyte Pharmaceuticals, Inc. Human gpcr proteins
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
CN1344321A (zh) 1998-12-28 2002-04-10 武田药品工业株式会社 筛选方法
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
AU2573900A (en) 1999-02-19 2000-09-04 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2000070347A1 (en) 1999-05-19 2000-11-23 Astrazeneca Ab Assays for agonists, agonists and inverse agonists of melanin concentrating hormone (mch) binding to the somatostatin-like receptor (slc-1)
AU5869100A (en) 1999-06-08 2000-12-28 Regents Of The University Of California, The Melanin concentrating hormone receptor
CA2378917A1 (en) 1999-07-14 2001-01-25 Merck & Co., Inc. Melanin-concentrating hormone receptor
CA2378403A1 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
WO2001021169A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Mch antagonists
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
EP1233981A4 (en) 1999-11-16 2003-02-12 Merck & Co Inc RECEPTOR COUPLED TO A G-PROTEIN
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
CA2402147A1 (en) 2000-03-15 2001-09-20 Merck & Co., Inc. Melanin concentrating hormone receptor chimeric and fusion proteins
JP2005229804A (ja) 2000-03-24 2005-09-02 Astellas Pharma Inc 新規なメラニンコンセントレーティングホルモン受容体
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
WO2002002744A2 (en) 2000-07-05 2002-01-10 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
US7273710B2 (en) 2000-07-05 2007-09-25 Takeda Pharmaceutical Company Limited Method for screening MCH receptor antagonist/agonist
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
WO2002004433A2 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
WO2002032897A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
HUP0302582A2 (hu) * 2000-12-22 2003-12-29 Schering Corp. Piperidin MCH antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk elhízás kezelésére
AU2002247367B2 (en) 2001-03-21 2005-10-27 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
CA2443672C (en) * 2001-04-12 2011-03-29 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
ES2319619T3 (es) 2001-05-04 2009-05-11 Amgen Inc. Compuestos heterociclicos condensados.
BR0209932A (pt) 2001-05-22 2004-10-13 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
US6664273B2 (en) * 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
WO2003060475A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
MXPA05004739A (es) * 2002-11-06 2005-08-02 Tularik Inc Compuestos heterociclicos fusionados.

Also Published As

Publication number Publication date
KR20050103184A (ko) 2005-10-27
US7253179B2 (en) 2007-08-07
WO2004043958A1 (en) 2004-05-27
NO20052655L (no) 2005-07-26
US20080058365A1 (en) 2008-03-06
CN101134757A (zh) 2008-03-05
ZA200503654B (en) 2006-09-27
AU2003285160B2 (en) 2009-06-04
JP2006508130A (ja) 2006-03-09
NO20052655D0 (no) 2005-06-02
CN1735613A (zh) 2006-02-15
JP4547266B2 (ja) 2010-09-22
CA2505372A1 (en) 2004-05-27
EA009421B1 (ru) 2007-12-28
MXPA05004739A (es) 2005-08-02
AU2003285160A1 (en) 2004-06-03
NZ540328A (en) 2008-02-29
US20040147538A1 (en) 2004-07-29
BR0316070A (pt) 2005-09-27
EA200500770A1 (ru) 2005-12-29
CN1330651C (zh) 2007-08-08
EP1562943A1 (en) 2005-08-17
IS7833A (is) 2005-05-02

Similar Documents

Publication Publication Date Title
EP1687002A4 (en) CONDENSED HETEROCYCLIC COMPOUNDS
IL174283A0 (en) Fused heterocyclic compounds
PL377087A1 (pl) Związki heterocykliczne
PT2042504E (pt) Derivados da azolepirimidina fundida
AU2003291310A8 (en) Fused heterocyclic compounds and use thereof
PL374544A1 (pl) Związki imidazo-skondensowane
ZA200603881B (en) Substituted fused heterocyclic C-glycosides
IL175489A0 (en) Substituted fused heterocyclic c-glycosides
IL165178A0 (en) Novel fused imidazole derivative
IL179414A0 (en) Fused heterocyclic compound
IL177933A0 (en) New compounds
IL166650A0 (en) New compounds
AU2003264018A8 (en) New compounds
IL163894A0 (en) New compounds
GB0315870D0 (en) Heterocyclic derivatives
PL378249A1 (pl) Skondensowane pochodne furanu
IL176384A0 (en) Novel fused pyrrolocarbazoles
MY142713A (en) Novel fused pyrrolocarbazoles
EP1737446A4 (en) CONDENSED HETEROCYCLIC COMPOUNDS
EP1476425A4 (en) Heterocyclic Aryl Sulphonamidocyclic Compounds
GB0120818D0 (en) Heterocyclic compounds
HU0203976D0 (en) New compounds
IS7833A (is) Efnasambönd með sameinaða heteróhringi
AU2003280578A1 (en) Heterocyclic compounds
GB0226609D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)